ReviewDiagnostics (Basel, Switzerland)2023
Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Non-Contrast MRI for Hepatocellular Carcinoma Surveillance and Diagnosis: A Systematic Review and Meta-Analysis of Diagnostic Accuracy.Journal of medical imaging and radiation oncology · 2026Pooled it
- Artificial Intelligence and Machine Learning Predicting Transarterial Chemoembolization Outcomes: A Systematic Review.Digestive diseases and sciences · 2025Pooled it
- Predicting early recurrence of craniopharyngioma using multi-omics radiomic modeling: a retrospective cohort study.Neurosurgical review · 2026Article
- Quantitative Hepatobiliary Phase Signal Analysis of HCC Nodules on Gd-EOB-DTPA-Enhanced MRI: A Potential Imaging Biomarker Associated with Disease Control After Conventional Transarterial Chemoembolization (cTACE).Journal of clinical medicine · 2026Article
- Review
- Dual-Phase Computed Tomography-Based Deep Learning Architecture for Three-Year Survival Prediction in Hepatocellular Carcinoma.Journal of imaging informatics in medicine · 2026Article
- Photon-Counting Detector Computed Tomography and Hepatocellular Carcinoma-A Systematic Review of the Current Evidence.Diagnostics (Basel, Switzerland) · 2026Review
- A combined radiomics and habitat analysis model for predicting early recurrence of HCC after liver transplantation.Frontiers in oncology · 2026Article
- Enhanced preoperative prediction for microvascular invasion in hepatocellular carcinoma through an optimized MR Radiomics combination strategy and machine learning predictor.Frontiers in medicine · 2026Article
- Association of week-2 Contrast-Enhanced Ultrasound Perfusion Changes with Response to Lenvatinib Plus PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study.Journal of hepatocellular carcinoma · 2026Article
- Personalized Mortality Risk Stratification in ALD- and MASLD-Related Hepatocellular Carcinoma Using a Machine Learning Approach.Metabolites · 2025Article
- Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications.World journal of hepatology · 2025Review
- Early screening for liver cancer must be performed.World journal of hepatology · 2025Review
- Emerging non-invasive imaging biomarkers of Ki-67 in pancreatic cancer: Toward predictive precision oncology.World journal of gastrointestinal oncology · 2025Article
- Review
- Enhancing LI-RADS Through Semi-Automated Quantification of HCC Lesions.Journal of personalized medicine · 2025Article
- Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2025Review
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
- Inter-reader agreement of RECIST and mRECIST criteria for assessing response to transarterial chemoembolization in hepatocellular carcinoma.BMC medical imaging · 2025Article
- Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.Journal of experimental & clinical cancer research : CR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains not only a cause of a considerable part of oncologic mortality, but also a diagnostic and therapeutic challenge for healthcare systems worldwide. Early detection of the disease and consequential adequate therapy are imperative to increase patients' quality of life and survival. Imaging plays, therefore, a crucial role in the surveillance of patients at risk, the detection and diagnosis of HCC nodules, as well as in the follow-up post-treatment. The unique imaging characteristics of HCC lesions, deriving mainly from the assessment of their vascularity on contrast-enhanced computed tomography (CT), magnetic resonance (MR) or contrast-enhanced ultrasound (CEUS), allow for a more accurate, noninvasive diagnosis and staging. The role of imaging in the management of HCC has further expanded beyond the plain confirmation of a suspected diagnosis due to the introduction of ultrasound and hepatobiliary MRI contrast agents, which allow for the detection of hepatocarcinogenesis even at an early stage. Moreover, the recent technological advancements in artificial intelligence (AI) in radiology contribute an important tool for the diagnostic prediction, prognosis and evaluation of treatment response in the clinical course of the disease. This review presents current imaging modalities and their central role in the management of patients at risk and with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.